(A) G-overhangs were not altered in U2OS cells treated with HU or aphidicolin (Aphi). Cells were treated for 24hrs, genomic DNA were purified and subjected to 2D gel analysis. G-overhangs are indicated by blue arrows. Values were then normalized with G-overhangs in untreated cells (Ctrl) to obtain relative abundance. Experiments were duplicated and the mean of relative abundance of G-overhangs was indicated.
(B) Zeocin or CPT treatment (24 h) leads to decrease of G-overhangs in U2OS (related to Fig 2D and 2F) . Values were then normalized with G-overhangs in untreated cells (Ctrl) to obtain relative abundance. Experiments were duplicated and the mean of relative abundance of G-overhangs was indicated.
(C) Schematic for zeocin treatment of U2OS cells during G1 or mid-S phase. U2OS cells were synchronized at G1/S with double thymidine. Cells were treated with zeocin/DMSO during G1 phase (end of second thymidine block) or during S phase (after 4hrs release from G1/S) for 2hrs.
(D) FACS analysis of U2OS cells treated with DMSO or zeocin during G1 or mid-S phase.
(E) and (F) Zeocin treatment during mid-S phase produces more C-circle and 5' Coverhangs than treatment during G1 phase. Error bars represent the mean ± SEM of three independent experiments.
(G) Zeocin or CPT treatment leads to increase of C-circle in VA13 cells. Error bars represent the mean ± SEM of three independent experiments. Two-tailed unpaired student's t-test was used to calculate P-values. ***P<0.001.
(H) Zeocin and CPT treatment leads to increase of 5' C-overhangs in VA13 cells. Coverhangs are indicated by red arrows. Values were then normalized with Coverhangs in untreated cells (Ctrl) to obtain relative abundance. Experiments were duplicated and the mean of relative abundance of C-overhangs was indicated.
